The Prostate Net

10/18/2026

Getting ready for the AACR Science of Cancer Health Disparities conference.
I will be speaking, mentoring, contributing and learning.

10/15/2026

Our colleague partner organization, Cancer Patients Europe, is asking for our support in promoting their new Cancer Patients Europe survey on tests, scans and new treatments for people living with metastatic prostate cancer that The Prostate Net has collaborated on previously.

The survey aims to better understand patients' and carers' awareness of and experiences with biomarkers and genetic testing, specialised scans and targeted treatments, as well as the information they receive and any barriers they may face in accessing these options.

The survey takes approximately 10 minutes to complete and is available in English, French, Italian, Spanish and German.

You can access the survey through this link and select your preferred language: https://cancerpatientseurope.org/cpe-launches-new-patient-survey-on-metastatic-prostate-cancer-tests-scans-and-treatments/

Every response can help CPE better understand patients' experiences and identify gaps in awareness and access to personalised prostate cancer care.

Thank you very much for your support in the global fight against prostate cancer!

Home » CPE Launches New Patient Survey on Metastatic Prostate Cancer Tests, Scans and TreatmentsCPE Launches New Patient Survey on Metastatic Prostate Cancer Tests, Scans and TreatmentsCancer Patients Europe (CPE) is proud to announce the launch of a new patient survey aimed at people living with m...

10/14/2026

Congratulations to Nico, a member of our colleague Dr. Joaquin Mateo's team, for this recognition of his work and support for his career in prostate cancer research.

09/30/2026

This is the last day of Prostate Cancer Awareness Month, but it should not be the last day of being vigilant of your prostate health or of the men around you.

Stay informed, do regular check-ups, and spread the word among your networks and communities.

09/28/2026

The psychological impact of cancer begins long before treatment is finished. But what happens when the treatment itself becomes the source of fear, uncertainty and emotional suffering?

Join us on Wednesday when we talk with Dra. Tania Estape on managing life after a diagnosis of cancer.

We will broadcast Live from 4:00 to 5:00PM CET (10:00AM EST) at:
Radio: 102.5FM - La Marina Cat
Internet: http://lamarina.cat/endirecte/
YouTube: https://www.youtube.com/

09/17/2026

Dr. Charles Ryan joined Virgil to talk about the "5 Questions Every Patient Should Ask When Their Prostate Cancer Changes"

Listen to his comments about how cancer can adapt, the biological basis of treatment resistance, the Himalayas-1 clinical trial of rinzimetostat, and more.

Join the conversation at:
- https://youtube.com/live/s98AzAgTKic

Understanding what is happening is the first step toward understanding what comes next.

The Prostate Net
We inform to fight!

09/15/2026

Join us tomorrow when Dr. Charles Ryan of Memorial Sloan Kettering Cancer Center talks with Virgil about "When prostate cancer becomes resistant, what happens next?"

We will explore the science—and the patient implications - of the Himalayas-1 Phase 3 clinical trial now evaluating rinzimetostat in combination with darolutamide in men with metastatic castration-resistant prostate cancer previously treated with abiraterone.

Tune in Wednesday, September 16 when we will broadcast Live from 4:00 to 5:00PM CET (10:00AM EST) at:
Radio: 102.5FM - La Marina Cat
Internet: http://lamarina.cat/endirecte/
YouTube: https://www.youtube.com/

Clinical research only works when patients and clinicians know the opportunities exist.

09/12/2026

When prostate cancer becomes resistant, what happens next?

Treatment resistance remains one of the major challenges in advanced prostate cancer.

The Himalayas-1 Phase 3 clinical trial is now evaluating rinzimetostat in combination with darolutamidein men with metastatic castration-resistant prostate cancer previously treated with abiraterone.

We will explore the science—and the patient implications—with Dr. Charles Ryan of Memorial Sloan Kettering Cancer Center on English Radio Barcelona Blue Voices.
Wednesday, September 16 | 4:00 PM CET / 10:00 AM EST

We'll discuss:
• The science behind rinzimetostat
• What Himalayas-1 is designed to determine
• Who may be eligible
• What patients should know before considering a clinical trial

Clinical research only works when patients and clinicians know the opportunities exist.

09/10/2026

09/10/2026

I am pleased to be part of the conversation tonight on the subject of evolving cancer treatments.

Join us for an insightful session as our expert speakers share the latest updates in prostate cancer and pediatric cancer treatment, exploring advances in care, treatment options, and what they mean for patients and families in Nigeria.

Tune in and join the conversation LIVE at: https://www.youtube.com/live/4IbUnKBJ3dA?si=t02fNOrA3FCxz3c-

2:00 PM EST
7:00 PM WAT (Lagos)
8:00 PM CET